(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Monday that Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoints of improving overall survival ...
From all my years in research and consulting, I think I’ve learned a thing or two about marketing worth sharing. Enduring fundamentals, mostly—yet often overlooked. So, over the course of my biweekly ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
“One Guinness, please!” a customer says to a barkeep, who flips a branded pint glass and catches it under the tap. The barkeep begins a multistep pour process lasting precisely 119.5 seconds, which, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback